Latest Materials News

Page 10 of 857
Genetic Signatures’ proposed Microba merger faces a formal challenge from 18.46% shareholder BCAL Diagnostics, which alleges the process lacks adequate protections and information for GSS investors. The Takeovers Panel has not yet appointed a sitting Panel or decided whether to open proceedings.
Ada Torres
Ada Torres
13 Nov 2026
PMET Resources enters the next stage of its Shaakichiuwaanaan project with C$168.9 million in cash, an 83.0 million-tonne probable lithium-tantalum reserve and a planned lithium-caesium-tantalum PEA. The six-month accounts also show rising project expenditure, no operating revenue and continued reliance on financing.
Maxwell Dee
Maxwell Dee
13 Nov 2026
Allan Gray has backed Majority Capital Partners’ proposed takeover of G8 Education, potentially strengthening the voting base for the non-binding scheme. Its support remains conditional on a binding agreement, independent expert approval and the absence of a superior offer.
Victor Sage
Victor Sage
13 Nov 2026
OpenLearning has secured a $500,000 investment from Philippine conglomerate World Citi Group, lifting commitments to its capital raising to approximately $1.48 million. The deal adds a potential technology partnership to a funding effort backed by record SaaS growth, but the larger entitlement offer still depends on shareholder participation.
Sophie Babbage
Sophie Babbage
13 Nov 2026
Big River Industries has agreed to a $1.62-a-share cash scheme with CTL, valuing its equity at approximately $156 million and securing support from shareholders controlling 59.5% of the register. The deal remains conditional on ACCC, Court, independent expert and shareholder approvals, with completion targeted for early 2027.
Victor Sage
Victor Sage
13 Nov 2026
Kincora Copper has used a US$10 million Mongolian asset sale and AngloGold Ashanti-backed exploration to broaden its New South Wales copper-gold portfolio. The quarter ended with approximately A$13 million in cash, but the unaudited accounts still flag material uncertainty over ongoing funding.
Maxwell Dee
Maxwell Dee
13 Nov 2026
Storage King Group has reaffirmed its FY27 distribution guidance at 4.5 cents per security, even as group occupancy fell towards the bottom of its target range and gearing increased. The self-storage operator is now leaning on internalisation savings, asset recycling and development lease-up to support the next phase of growth.
Eva Park
Eva Park
13 Nov 2026
RBR Group has secured A$600,000 through a placement and reworked all A$1.25 million of its convertible notes, giving it near-term funding to deliver its first post-restart Rovuma LNG contract. The financing strengthens the bridge to execution, but leaves shareholders facing further dilution and the company still dependent on future awards.
Victor Sage
Victor Sage
13 Nov 2026
Australian Bond Exchange says FY2026 marked a sharper recovery, with revenue up 47% and two consecutive quarters of positive operating cash flow. But the ASX-listed fixed-income group remains loss-making, carries $2 million of convertible-note maturities in 2027 and faces a going-concern uncertainty.
Claire Turing
Claire Turing
13 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Senetas says its core encryption business is gaining traction across newer markets, but the next year will test whether product growth and Thales inventory can translate into stronger earnings. The company also flagged a possible Menlo Security liquidity event, while stressing that no transaction has been announced.
Sophie Babbage
Sophie Babbage
13 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026

Browse the archive

Full archive